Why is Shanghai Henlius Biotech stock climbing today?
Shanghai Henlius Biotech's stock climbed 1.2% to HK$68.1 on Monday following the announcement of a strategic collaboration with Swiss generics major Sandoz. Under the agreement, Henlius grants Sandoz exclusive rights for registration and commercialization outside China for up to 10 partnered assets across major disease areas such as oncology, autoimmune diseases, and ophthalmic diseases.
This collaboration is viewed as a significant de-risking factor for Henlius' international expansion, bolstering the company's long-term revenue diversification strategy. The stock rise also coincided with a broader uptick in Hong Kong markets, where the Hang Seng index increased by 1.5%.
Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
